Dear Representative Paulsen:
The American Association for Clinical Chemistry (AACC) endorses H.R.184, the “Protect Medical
Innovation Act,” which would repeal the 2.3 percent excise tax imposed on medical devices as part of the
2010 Affordable Care Act (ACA). AACC believes it is critical that Congress repeal this tax, otherwise
the tax could adversely affect the development of new technologies crucial to improving patient care.
AACC is a global scientific and medical professional organization dedicated to clinical laboratory science
and its application to healthcare. AACC brings together more than 50,000 clinical laboratory
professionals, physicians, research scientists, and business leaders from around the world focused on
clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management,
and other areas of laboratory science to advance healthcare collaboration, knowledge, expertise, and
Over the past few decades, advances in medical technology have contributed to significant gains in
patient health outcomes. This progress, according to the Advanced Medical Technology Association
(AdvaMed), has contributed to a 16% reduction in annual mortality, a 25% cut in disability rates, a 56%
cut in hospital days, and a 3.2 year increase in life expectancy.
Higher taxes on device manufacturers jeopardize these improvements. A 2013 survey of medical device
manufacturers conducted by AdvaMed--during the first year of the tax—showed that nearly one in three
manufacturers had cut investment in research and development in light of this tax. The good news is that
Congress intervened and temporarily suspended the tax. Unfortunately, this tax deferment ends at the end
of 2017. AACC strongly supports H.R.184, which would permanently repeal the medical device excise
We look forward to working with you on this important matter. If you have any questions, please email
Vince Stine, PhD, AACC Director of Government Affairs, at email@example.com.
Michael J. Bennett PhD, FRCPath, FACB, DABCC